*7859 REDEFINE 8: Long term weight management benefits of CagriSema in people with obesity
Research type
Research Study
Full title
Long-term efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) once weekly versus placebo in participants with obesity
IRAS ID
1010538
Contact name
Clinical Transparency
Contact email
Sponsor organisation
Novo Nordisk A/S
Eudract number
2024-512144-39
ISRCTN Number
N/A
Clinicaltrials.gov Identifier
N/A
Research summary
People living with obesity are more likely to get diseases like type 2 diabetes, increased blood pressure and diseases of the heart. Obesity is treated with diet and physical activity, but this does not result in a weight loss for all people. Some people may need treatment for obesity on top of lifestyle changes to lose weight. The study medicine CagriSema is a combination of two medicines named cagrilintide and semaglutide, which may help people lose weight. In this study, we want to see how well CagriSema can help people to lose weight compared to a dummy medicine (also called placebo), which looks like the study medicine but has no effect. This study is also looking at whether weight lost with CagriSema can be maintained on a lower dose. All participants will receive counselling on diet and physical activity during the study.
REC name
London - Brent Research Ethics Committee
REC reference
24/LO/0711
Date of REC Opinion
9 Dec 2024
REC opinion
Further Information Favourable Opinion